Recombinant Human Filaggrin, GST-tagged

• Cat.No.: FLG-1367H
• Product Overview: Recombinant Human Filaggrin expressed inE.coli, shows a 53 kDa SDS-PAGE (Including GST). The Filaggrin is purified by proprietary chromatographic techniques.

Specification

• Cat. No.: FLG-1367H
• Description: Filaggrins are an important class of the intermediate filament-associated proteins which interact with keratin intermediate filaments (Ifs) of terminally differentiating mammalian epidermis. Filaggrins exhibit wide species variations. Filaggrin also appears to be a target molecule for rheumatoid arthritis-specific auto-antibodies in humans. Profilaggrin is a key protein component of the keratohyalin granules of mammalian epidermis. It is primarily expressed as a large polyprotein precursor which is later proteolytically processed into individual functional filaggrin molecules. Persons with truncation mutations in the filaggrin gene, are strongly predisposed to a severe form of dry skin, (ichthyosis vulgaris), and/or eczema. It was shown that approximately 50% of all severe cases of eczema may have at least one mutated filaggrin gene. Truncation mutations R501X and 2284del4 are the most widespread mutations in the caucasian population, with 7-10% of the caucasian population carrying at least one copy of these mutations. R501X and 2284del4 are not usually found in non-caucasian individuals, nevertheless novel mutations (3321delA and S2554X) have been found in Japanese populations that yield similar effects.
• Source: Escherichia Coli.
• Physical Appearance: Sterile Filtered clear solution.
• Applications: • ELISA • Inhibition Assays • Western Blotting.
• Formulation: Filaggrin at 100µg/ml in 50mM Tris-Acetate, pH7.5, 1mM EDTA and 20% Glycerol.
• Stability: Store vial at -20°C to -80°C. When stored at the recommended temperature, this protein is stable for 12 months. Please prevent freeze-thaw cycles.

Gene Information

• Gene Name: FLG filaggrin [ Homo sapiens ]
• Synonyms: Filaggrin; ATOD2; FLG; epidermal filaggrin; OTTHUMP00000014057
• Gene ID: 2312
• mRNA Refseq: NM_002016
• Protein Refseq: NP_002007
• MIM: 135940
• UniProt ID: P20930
• Chromosome Location: 1q21.3
• Function: calcium ion binding; structural molecule activity

Reviews

10/20/2022

Catalytic activity is excellent, and the catalytic performance is stable regardless of the environment

07/03/2021

Will not interact with other reagents, will not affect.

01/14/2021

The quality is very good, and their service life is very long, I am very satisfied with this product.

Q&As

Is there a drug that targets the FLG protein?

There are currently no drugs that directly target FLG protein, but there are some drugs that can affect the expression level and activity of FLG protein, such as some growth factors and cytokines.

How is atopic dermatitis caused by FLG gene mutations treated?

For atopic dermatitis caused by FLG gene mutations, treatments for inflammation and itching, such as topical glucocorticoids, antihistamines, etc., can also be used for systemic treatments, such as immunosuppressants and biologics.

How do mutations in the FLG protein cause skin diseases?

Mutations in the FLG protein can cause abnormal keratin fiber structure in keratinocytes, affecting the maturation and differentiation of the stratum corneum, resulting in symptoms such as dryness, scaling, and itching.

Can genetic diagnostics be Used to identify FLG mutations in patients with atopic dermatitis?

Gene sequencing technology can be used to detect FLG gene mutations in patients with atopic dermatitis, so as to provide a basis for diagnosis and treatment.

How is FLG protein related to atopic dermatitis?

Patients with atopic dermatitis often have mutations in the FLG gene, which lead to impaired skin barrier function, which in turn causes symptoms such as skin inflammation and itching.

Can skin diseases caused by mutations in the FLG protein be treated?

Treatment of skin diseases caused by FLG protein mutations includes topical moisturizers, keratin softeners, and anti-inflammatory drugs, as well as systemic treatments such as oral medications, biologics, etc.